secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001837607-25-000065
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma reports Q2 2025 cash of $8.4M; advancing ABP-450 biosimilar milestones
--------------------------------------------------------------------------------

- Cash and equivalents $8.4M as of June 30, 2025; expected to fund operations through Q4 2025 and Type 2a FDA meeting.
- Primary structure and select functional analyses for ABP-450 expected to complete in Q3 2025.
- Type 2a meeting with FDA on 351(k) biosimilar pathway anticipated in Q4 2025.
- Pursuing ABP-450 as BOTOX biosimilar for all therapeutic indications; over $3B U.S. therapeutic market opportunity noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/0001837607-25-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/aeon-20250812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer